CLINICAL TRIALS PROFILE FOR ULIMORELIN
✉ Email this page to a colleague
Clinical Trials for Ulimorelin
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT01285570 ↗ | Ulimorelin Study of Efficacy and Safety (ULISES 007) | Completed | Norgine | Phase 3 | Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection. |
NCT01285570 ↗ | Ulimorelin Study of Efficacy and Safety (ULISES 007) | Completed | Tranzyme, Inc. | Phase 3 | Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection. |
NCT01296620 ↗ | Ulimorelin Study of Efficacy and Safety (ULISES 008) | Completed | Norgine | Phase 3 | Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection |
NCT01296620 ↗ | Ulimorelin Study of Efficacy and Safety (ULISES 008) | Completed | Tranzyme, Inc. | Phase 3 | Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Ulimorelin
Condition Name
Clinical Trial Locations for Ulimorelin
Trials by Country
Clinical Trial Progress for Ulimorelin
Clinical Trial Phase
Clinical Trial Sponsors for Ulimorelin
Sponsor Name